Chemistry:Tariquidar
From HandWiki
Tariquidar (INN/USAN) is a potent P-glycoprotein inhibitor and a substrate of breast cancer protein (BCRP/ABCG2)[1] undergoing research as an adjuvant against multi-drug resistance in cancer.[2]
Tariquidar progressed to phase III clinical trials in combination with vinorelbine in an effort to enhance the efficacy of this chemotherapeutic agent. However, several of these trials were terminated early due to adverse effects, and further development of Tariquidar was subsequently halted.[3]
References
- ↑ "Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein" (in en). Drug Metabolism and Disposition: The Biological Fate of Chemicals 44 (2): 275–282. February 2016. doi:10.1124/dmd.115.067785. PMID 26658428.
- ↑ "Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor". Expert Review of Anticancer Therapy 7 (4): 447–459. April 2007. doi:10.1586/14737140.7.4.447. PMID 17428165.
- ↑ "Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer". Current Opinion in Pharmacology 6 (4): 350–354. August 2006. doi:10.1016/j.coph.2006.01.009. PMID 16690355.
 |  |
